(RTTNews) – Shares of Tonix Pharmaceuticals Holding Corp. (TNXP), a New York-based biopharmaceutical company, are surging more than 38 percent or $0.59 in Tuesday’s morning trade at $2.14 despite no company-specific news influencing the stock.
U.S. stocks are rising on Tuesday in reaction to news that European Union leaders agreed to a 750 billion euro stimulus package to tackle the exceptional nature of the economic and social situation posed by the coronavirus pandemic. Upbeat earnings results from IBM Corp. and Coca-Cola also boosted sentiment.
Last Thursday, Tonix Pharmaceuticals said it entered into a research collaboration and option agreement with Columbia University to develop precision medicine techniques for COVID-19 vaccines and therapeutics.
The research collaboration will focus on T cell and antibody responses to SARS-CoV-2, the virus that causes COVID-19 at the cellular level, including human monoclonal antibodies and anti-idiotypes.
Tonix Pharmaceuticals has traded in a range of $0.39 to $5.90 in the past 52 weeks.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
More Stories
New Forever 21 CEO plots post-bankruptcy comeback with physical stores
The New Laws Trying to Take the Anxiety Out of Shopping
Shop Prime Day savings before Black Friday